fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Glycopyrrolate

7 Limited Use · 3 not a benefit

Glycopyrrolate Injection · DIN 02382857 · 0.2 mg/mL · injection solution

Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Glycopyrrolate Injection · DIN 02382857 Manufacturer: Omega Laboratories Ltd.; listing date 2015-03-31 Health Canada: Marketed since 2012-06-29 · brand GLYCOPYRROLATE INJECTION · ATC A03AB02 GLYCOPYRRONIUM · form Liquid · route Intramuscular, Intravenous · ingredients GLYCOPYRROLATE 0.2 MG/ML · company Omega laboratories limited · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Glycopyrrolate Injection: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02382857)

Source record
DIN 02382857: Glycopyrrolate Injection Raw flags: sec12=Y, sec3=Y Item: 120808010; group id 214; item number 0388; lccId 00288; manufacturer id OMG Source form: Inj Sol; strength: 0.2mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.7825; ministry $2.7825 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02382857 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86866
Interchangeable products
Glycopyrrolate Injection USP · DIN 02473879 · $2.7825 Robinul · DIN 02043610 · not recorded Sandoz Glycopyrrolate · DIN 02039508 · $2.7825
Shortage status: shortage reported ended September 3, 2026 (report last updated September 3, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02382857
Shortage record checked October 6, 2026

Glycopyrrolate Injection USP · DIN 02473879 · 0.2 mg/mL · injection solution

Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Glycopyrrolate Injection USP · DIN 02473879 Manufacturer: Sterimax Inc.; listing date 2022-08-31 Health Canada: Marketed since 2021-05-26 · brand GLYCOPYRROLATE INJECTION USP · ATC A03AB02 GLYCOPYRRONIUM · form Solution · route Intravenous, Intramuscular · ingredients GLYCOPYRROLATE 0.2 MG/1ML · company Sterimax inc · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Glycopyrrolate Injection USP: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02473879)

Source record
DIN 02473879: Glycopyrrolate Injection USP Raw flags: sec12=Y, sec3=Y Item: 120808010; group id 214; item number 0388; lccId 00288; manufacturer id STE Source form: Inj Sol; strength: 0.2mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.7825; ministry $2.7825 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02473879 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96360
Interchangeable products
Glycopyrrolate Injection · DIN 02382857 · $2.7825 Robinul · DIN 02043610 · not recorded Sandoz Glycopyrrolate · DIN 02039508 · $2.7825
Shortage status: resolved shortage (ended March 11, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02473879
Shortage record checked October 6, 2026

Sandoz Glycopyrrolate · DIN 02039508 · 0.2 mg/mL · injection solution

Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Sandoz Glycopyrrolate · DIN 02039508 Manufacturer: Sandoz Canada Inc.; listing date 2017-07-31 Health Canada: Marketed since 2005-09-21 · brand GLYCOPYRROLATE INJECTION USP · ATC A03AB02 GLYCOPYRRONIUM · form Solution · route Intravenous, Intramuscular · ingredients GLYCOPYRROLATE 0.2 MG/ML · company Sandoz canada incorporated · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Glycopyrrolate: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02039508)

Source record
DIN 02039508: Sandoz Glycopyrrolate Raw flags: sec12=Y, sec3=Y Item: 120808010; group id 214; item number 0388; lccId 00288; manufacturer id SDZ Source form: Inj Sol; strength: 0.2mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.7825; ministry $2.7825 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02039508 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14577
Interchangeable products
Glycopyrrolate Injection · DIN 02382857 · $2.7825 Glycopyrrolate Injection USP · DIN 02473879 · $2.7825 Robinul · DIN 02043610 · not recorded
Shortage status: resolved shortage (ended March 30, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02039508
Shortage record checked October 6, 2026

Glycopyrrolate Injection USP · DIN 02473895 · 0.4 mg/2 mL · injection solution (Preservative Free)

Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Glycopyrrolate Injection USP · DIN 02473895 Manufacturer: Sterimax Inc.; listing date 2022-08-31 Health Canada: Marketed since 2021-05-26 · brand GLYCOPYRROLATE INJECTION USP · ATC A03AB02 GLYCOPYRRONIUM · form Solution · route Intravenous, Intramuscular · ingredients GLYCOPYRROLATE 0.4 MG/2ML · company Sterimax inc · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Glycopyrrolate Injection USP: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02473895)

Source record
DIN 02473895: Glycopyrrolate Injection USP Raw flags: sec12=Y, sec3=Y Item: 120808014; group id 214; item number 0389; lccId 00288; manufacturer id STE Source form: Inj Sol (Preservative Free); strength: 0.4mg/2mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.7825; ministry $2.7825 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02473895 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96361
Interchangeable products
Glycopyrrolate Injection USP · DIN 02513749 · $2.7825 Robinul · DIN 09858163 · not recorded
Shortage status: resolved shortage (ended March 11, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02473895
Shortage record checked October 6, 2026

Glycopyrrolate Injection USP · DIN 02513749 · 0.4 mg/2 mL · injection solution (Preservative Free)

Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Glycopyrrolate Injection USP · DIN 02513749 Manufacturer: Jamp Pharma Corporation; listing date 2024-08-30 Health Canada: Marketed since 2022-04-01 · brand GLYCOPYRROLATE INJECTION USP · ATC A03AB02 GLYCOPYRRONIUM · form Solution · route Intramuscular, Intravenous · ingredients GLYCOPYRROLATE 0.2 MG/ML · company Jamp pharma corporation · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Glycopyrrolate Injection USP: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02513749)

Source record
DIN 02513749: Glycopyrrolate Injection USP Raw flags: sec12=Y, sec3=Y Item: 120808014; group id 214; item number 0389; lccId 00288; manufacturer id JPC Source form: Inj Sol (Preservative Free); strength: 0.4mg/2mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.7825; ministry $2.7825 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02513749 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100293
Interchangeable products
Glycopyrrolate Injection USP · DIN 02473895 · $2.7825 Robinul · DIN 09858163 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02513749
Shortage record checked October 6, 2026

Glycopyrrolate Injection USP · DIN 02473887 · 4 mg/20 mL · injection solution (With Preservative)

Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Glycopyrrolate Injection USP · DIN 02473887 Manufacturer: Sterimax Inc.; listing date 2022-08-31 Health Canada: Marketed since 2021-05-26 · brand GLYCOPYRROLATE INJECTION USP · ATC A03AB02 GLYCOPYRRONIUM · form Solution · route Intravenous, Intramuscular · ingredients GLYCOPYRROLATE 4 MG/20ML · company Sterimax inc · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Glycopyrrolate Injection USP: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02473887)

Source record
DIN 02473887: Glycopyrrolate Injection USP Raw flags: sec12=Y, sec3=Y Item: 120808015; group id 214; item number 0390; lccId 00288; manufacturer id STE Source form: Inj Sol (With Preservative); strength: 4mg/20mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.7825; ministry $2.7825 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02473887 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96362
Interchangeable products
Glycopyrrolate Injection USP · DIN 02532379 · $2.7825 Robinul · DIN 09858164 · not recorded
Shortage status: resolved shortage (ended May 27, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02473887
Shortage record checked October 6, 2026

Glycopyrrolate Injection USP · DIN 02532379 · 4 mg/20 mL · injection solution (With Preservative)

Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Glycopyrrolate Injection USP · DIN 02532379 Manufacturer: Jamp Pharma Corporation; listing date 2024-03-28 Health Canada: Marketed since 2024-01-18 · brand GLYCOPYRROLATE INJECTION USP · ATC A03AB02 GLYCOPYRRONIUM · form Solution · route Intramuscular, Intravenous · ingredients GLYCOPYRROLATE 0.2 MG/ML · company Jamp pharma corporation · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Glycopyrrolate Injection USP: Formulary list price $2.78 per unit (the source does not state the unit; exact figure $2.7825). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02532379)

Source record
DIN 02532379: Glycopyrrolate Injection USP Raw flags: sec12=Y, sec3=Y Item: 120808015; group id 214; item number 0390; lccId 00288; manufacturer id JPC Source form: Inj Sol (With Preservative); strength: 4mg/20mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.7825; ministry $2.7825 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02532379 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102141
Interchangeable products
Glycopyrrolate Injection USP · DIN 02473887 · $2.7825 Robinul · DIN 09858164 · not recorded
Shortage status: resolved shortage (ended April 10, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02532379
Shortage record checked October 6, 2026

Robinul · PIN 09858163 · 0.4 mg/2 mL · injection solution (Preservative Free)

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Ontario Limited Use criteria, code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Robinul · DIN 09858163 Manufacturer: Wyeth-Ayerst Canada Inc.; listing date 2022-08-31 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Robinul: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858163)

Source record
DIN 09858163: Robinul Raw flags: notABenefit=Y, sec3=Y Item: 120808014; group id 214; item number 0389; lccId 00288; manufacturer id WYA Source form: Inj Sol (Preservative Free); strength: 0.4mg/2mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858163 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Glycopyrrolate Injection USP · DIN 02473895 · $2.7825 Glycopyrrolate Injection USP · DIN 02513749 · $2.7825
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858163
Shortage record checked October 6, 2026

Robinul · PIN 09858164 · 4 mg/20 mL · injection solution (With Preservative)

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Ontario Limited Use criteria, code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Robinul · DIN 09858164 Manufacturer: Wyeth-Ayerst Canada Inc.; listing date 2022-08-31 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Robinul: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858164)

Source record
DIN 09858164: Robinul Raw flags: notABenefit=Y, sec3=Y Item: 120808015; group id 214; item number 0390; lccId 00288; manufacturer id WYA Source form: Inj Sol (With Preservative); strength: 4mg/20mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858164 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Glycopyrrolate Injection USP · DIN 02473887 · $2.7825 Glycopyrrolate Injection USP · DIN 02532379 · $2.7825
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858164
Shortage record checked October 6, 2026

Robinul · DIN 02043610 · 0.2 mg/mL · injection solution

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-03-07 — choose a marketed DIN from the same-category list.Discontinued March 7, 2000 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-03-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-03-07 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Robinul · DIN 02043610 Manufacturer: Wyeth-Ayerst Canada Inc.; listing date 2015-03-31 Health Canada: Cancelled post market since 2000-03-07 · brand ROBINUL 0.2MG/ML LIQ INJ · ATC A03AB02 GLYCOPYRRONIUM · form Liquid · route Intravenous, Intramuscular · ingredients GLYCOPYRROLATE .2 MG/ML · company Wyeth-ayerst canada inc. · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Robinul: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02043610)

Source record
DIN 02043610: Robinul Raw flags: notABenefit=Y, sec3=Y Item: 120808010; group id 214; item number 0388; lccId 00288; manufacturer id WYA Source form: Inj Sol; strength: 0.2mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02043610 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15891
Interchangeable products
Glycopyrrolate Injection · DIN 02382857 · $2.7825 Glycopyrrolate Injection USP · DIN 02473879 · $2.7825 Sandoz Glycopyrrolate · DIN 02039508 · $2.7825
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02043610
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since March 7, 2000 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (12:08:08 Antimuscarinics/Antispasmodics) and how they are covered

Matched class: 12:08:08 Antimuscarinics/Antispasmodics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM 12:08:08 Antimuscarinics/Antispasmodics

TIOTROPIUM BROMIDE MONOHYDRATE

· 4 products · General benefit · strengths: 18mcg, 2.5mcg/Actuation · Inh Cap, Inh Sol-60 Actuation Pk

UMECLIDINIUM

· 1 products · General benefit · strengths: 62.5mcg · Blister Pd Inh-30 Dose Pk

HYOSCINE BUTYLBROMIDE

· 1 products · Limited Use, codes 481 · strengths: 20mg/mL · Inj Sol

TIOTROPIUM BROMIDE MONOHYDRATE & OLODATEROL HYDROCHLORIDE

· 1 products · Limited Use, codes 459 · strengths: 2.5mcg & 2.5mcg/Actuation · Inh Sol-60 Actuation Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:08:08
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications GLYCOPYRROLATE INJECTION USP is indicated for: • Gastrointestinal Disorders: GLYCOPYRROLATE INJECTION USP may be used in the management of gastrointestinal disorders amenable to anticholinergic therapy when oral medication is not tolerated or a rapid anticholinergic effect is desired. • Anesthesia: GLYCOPYRROLATE INJECTION USP is of value as a preanesthetic antimuscarinic agent. Due to its benzyl alcohol content, GLYCOPYRROLATE INJECTION USP when packaged in multidose vials should not be used in children less than 3 years of age or in newborns. See 2 Contraindications. • Reversal of Neuromuscular Blockade: During reversal of neuromuscular blockade induced by nondepolarizing muscle relaxants, it protects against the peripheral muscarinic effects (e.g. bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine. 1.1. Pediatrics Pediatrics (<18 years of age): No data are available to Health Canda on the use of GLYCOPYRROLATE INJECTION USP in the management of gastrointestinal disorders in children; therefore Health Canada has not authorized this indication for pediatric use. … https://pdf.hres.ca/dpd_pm/00082645.PDF PM date: 2025-12-02 Source product: GLYCOPYRROLATE INJECTION USP; DIN 02039508; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Glycopyrrolate Injection · DIN 02382857 Shortage status: shortage reported ended 2026-09-03 (report last updated 2026-09-03); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02382857

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Robinul: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026